Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year.LAS VEGAS Las Vegas (läs vā`gəs), city (1990 pop. 258,295), seat of Clark co., S Nev.; inc. 1911. It is the largest city in Nevada and the center of one of the fastest-growing urban areas in the United States. -- Samaritan Pharmaceuticals Inc. (AMEX AMEX See: American Stock Exchange :LIV) --David W. Munno, Merrill Lynch Merrill Lynch & Co., Inc. (NYSE: MER TYO: 8675 ), through its subsidiaries and affiliates, provides capital markets services, investment banking and advisory services, wealth management, asset management, insurance, banking and related products and services on a global basis. VP of biotechnology, stated, "Large-cap biotech firms need some blockbuster products for meaningful growth which is more than likely to come from small- to mid-sized biotechs." --Vinny Jindal, of Think Equity Partners LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , stated, "Small-cap biotech is going to have a banner year." Samaritan Pharmaceuticals Inc., a developer of innovative drugs, announced today that biotech analysts at Bio 2006 in Chicago, the industry's largest conference, predicted encouraging trends for small-caps like Samaritan. Dr. Greeson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Samaritan, stated, "We found a much stronger interest in our blockbuster technology than ever before at Bio 2006, which we think might confirm the analyst predictions that large-caps need product. We also found a warm reception to explore in-licensing opportunities to market and distribute niche products in Greece and Eastern Europe Eastern Europe The countries of eastern Europe, especially those that were allied with the USSR in the Warsaw Pact, which was established in 1955 and dissolved in 1991. . We are extremely pleased with the interest we have garnered." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap biotech, driven to discover, develop, and commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease. Look at www.samaritanpharma.com. Please register on our Web site so we can notify you of upcoming conference calls, news and events. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed April 15, 2005. The company undertakes no duty to update forward-looking statements. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion